Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 7/20 | 1.00 |
| ▸ | TACR3 | P29371 | 7/20 | 1.00 |
| ▸ | TRPV4 | Q9HBA0 | 15/20 | 0.80 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.68 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5203642 | 0.84 | TRPV4 (0.73) | TACR2TACR3TRPV4OPRM1KCNH2 | |
| SCHEMBL2373330 | 0.84 | TRPV4 (0.72) | TACR2TACR3TRPV4OPRM1KCNH2 | |
| SCHEMBL6392934 | 0.83 | TRPV4 (0.82) | TACR2TACR3TRPV4OPRM1KCNH2 | |
| SCHEMBL5945344 | 0.83 | TRPV4 (0.80) | TACR2TACR3TRPV4OPRM1KCNH2 | |
| SCHEMBL5945397 | 0.83 | TACR3 (0.77) | TACR2TACR3TRPV4OPRM1KCNH2 | |
| SCHEMBL5945410 | 0.83 | TACR2 (0.89) | TACR2TACR3TRPV4OPRM1KCNH2 | |
| SCHEMBL5945443 | 0.83 | TACR2 (0.85) | TACR2TACR3TRPV4OPRM1KCNH2 | |
| Hydrochloric Acid SCHEMBL5733490 | 0.83 | TRPV4 (0.71) | TACR2TACR3TRPV4OPRM1KCNH2 | |
| SCHEMBL6390680 | 0.82 | TACR2 (0.81) | TACR2TACR3TRPV4OPRM1KCNH2 | |
| SCHEMBL5945383 | 0.82 | TRPV4 (0.86) | TACR2TACR3TRPV4OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090795-A1 | Pharmaceutical Compositions Based on Nk2 Antagonists for Pediatric Use | LABORATORI GUIDOTTI S.P.A. (IT) | 2008-04-17 | — | — | US | claimed |
| EP-1809267-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON NK2 ANTAGONISTS FOR PEDIATRIC USE | Laboratori Guidotti S.P.A. (IT) | 2007-07-25 | — | — | EP | claimed |
| WO-2006045820-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON NK2 ANTAGONISTS FOR PEDIATRIC USE | LABORATORI GUIDOTTI S.P.A. (IT) | 2006-05-04 | — | — | WO | claimed |
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-20220288028-A1 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2022-09-15 | — | — | US | disclosed |
| EP-3976594-A1 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | The Schepens Eye Research Institute, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114206849-A | Therapeutic methods for treating non-infectious ocular immunoinflammatory disorders | 斯格本斯眼科研究所有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-9556200-B2 | Tricyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-31 | — | — | US | disclosed |
| EP-2824106-B1 | TRICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-20150045351-A1 | TRICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-12 | — | — | US | disclosed |
| EP-2824106-A1 | TRICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-01-14 | — | — | EP | disclosed |
| WO-2013133325-A1 | TRICYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2013-09-12 | — | — | WO | disclosed |
| US-20100234284-A1 | Pharmaceutical compositions based on NK2 antagonists for pediatric use | ALEOTTI ALBERTO | 2010-09-16 | — | — | US | disclosed |
| US-7727955-B2 | Pharmaceutical compositions based on NK2 antagonists for pediatric use | LABORATORI GUIDOTTI S.P.A. (IT) | 2010-06-01 | — | — | US | disclosed |
| US-20080090795-A1 | Pharmaceutical Compositions Based on Nk2 Antagonists for Pediatric Use | LABORATORI GUIDOTTI S.P.A. (IT) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045351-A1 | TRICYCLIC COMPOUND | HTR2C, HTR1A, HTR2A | TACR2 68/4885TACR3 287/4885TRPV4 351/4885 |
| US-20220288028-A1 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | MSR1, LTB4R2, LTB4R | TACR2 44/4885TACR3 714/4885TRPV4 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.